Abinaya Muthusamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abinaya Muthusamy has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrew S. Mendiola
Gladstone Institutes, San Francisco, USA
1 shared publication Anke Meyer-Franke
Gladstone UCSF Center for Neurovascular Brain Immunology, San Francisco, CA 94158, USA
1 shared publicationBelinda Cabriga
Gladstone UCSF Center for Neurovascular Brain Immunology, San Francisco, CA 94158, USA
1 shared publicationEric A Bushong
National Center for Microscopy and Imaging Research, Center for Research on Biological Systems, University of California, San Diego, La Jolla, CA 92093, USA
1 shared publicationHans Lassmann
Center for Brain Research, Medical University of Vienna, A-1090 Vienna, Austria
1 shared publicationJae Kyu Ryu
Gladstone UCSF Center for Neurovascular Brain Immunology, San Francisco, CA 94158, USA
1 shared publication
Latest Publications
- Open Access
- 24 August 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (8) , 2291-2301
BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis
Extrinsic inhibitors at sites of blood–brain barrier disruption and neurovascular damage contribute to remyelination failure in neurological diseases. However, therapies to overcome the extrinsic inhibition of remyelination are not widely available and the dynamics of glial progenitor niche remodelling at sites of neurovascular dysfunction are largely unknown. By integrating in vivo two-photon imaging co-registered with electron microscopy and transcriptomics in chronic neuroinflammatory lesions, we found that oligodendrocyte precursor cells clustered perivascularly at sites of limited remyelination with deposition of fibrinogen, a blood coagulation factor abundantly deposited in multiple sclerosis lesions. By developing a screen (OPC-X-screen) to identify compounds that promote remyelination in the presence of extrinsic inhibitors, we showed that known promyelinating drugs did not rescue the extrinsic inhibition of remyelination by fibrinogen. In contrast, bone morphogenetic protein type I receptor blockade rescued the inhibitory fibrinogen effects and restored a promyelinating progenitor niche by promoting myelinating oligodendrocytes, while suppressing astrocyte cell fate, with potent therapeutic effects in chronic models of multiple sclerosis. Thus, abortive oligodendrocyte precursor cell differentiation by fibrinogen is refractory to known promyelinating compounds, suggesting that blockade of the bone morphogenetic protein signalling pathway may enhance remyelinating efficacy by overcoming extrinsic inhibition in neuroinflammatory lesions with vascular damage.
- 24 August 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (8) , 2291-2301
Open AccessBMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis
Extrinsic inhibitors at sites of blood–brain barrier disruption and neurovascular damage contribute to remyelination failure in neurological diseases. However, therapies to overcome the extrinsic inhibition of remyelination are not widely available and the dynamics of glial progenitor niche remodelling at sites of neurovascular dysfunction are largely unknown. By integrating in vivo two-photon imaging co-registered with electron microscopy and transcriptomics in chronic neuroinflammatory lesions, we found that oligodendrocyte precursor cells clustered perivascularly at sites of limited remyelination with deposition of fibrinogen, a blood coagulation factor abundantly deposited in multiple sclerosis lesions. By developing a screen (OPC-X-screen) to identify compounds that promote remyelination in the presence of extrinsic inhibitors, we showed that known promyelinating drugs did not rescue the extrinsic inhibition of remyelination by fibrinogen. In contrast, bone morphogenetic protein type I receptor blockade rescued the inhibitory fibrinogen effects and restored a promyelinating progenitor niche by promoting myelinating oligodendrocytes, while suppressing astrocyte cell fate, with potent therapeutic effects in chronic models of multiple sclerosis. Thus, abortive oligodendrocyte precursor cell differentiation by fibrinogen is refractory to known promyelinating compounds, suggesting that blockade of the bone morphogenetic protein signalling pathway may enhance remyelinating efficacy by overcoming extrinsic inhibition in neuroinflammatory lesions with vascular damage.